miR-204-5p and miR-3065-5p exert antitumor effects on melanoma cells

Oncology Letters
Nadezhda PalkinaTatiana Ruksha

Abstract

MicroRNA (miR)-204-5p was previously identified to be downregulated in melanoma compared with melanocytic nevi. This observation prompted a functional study on miR-204-5p and the newly-identified miR-3065-5p, two miRNAs suggested to be tumor-suppressive oncomiRs. Application of miR-204-5p mimics or inhibitors resulted in a decrease or increase, respectively, in melanoma cell proliferation and colony formation. miR-204-5p mimics hindered invasion, whereas miR-204-5p inhibitors stimulated cancer cell migration. Modulation of miR-3065-5p led to a decrease in melanoma cell proliferation, altered cell cycle distribution and increased expression levels of its target genes HIPK1 and ITGA1, possibly due to functional modifications identified in these cells. miR-204-5p and miR-3065-5p demonstrated antitumor capacities that may need to be taken into account in the development of melanoma treatment approaches.

Citations

May 11, 2021·Frontiers in Oncology·Soudeh Ghafouri-FardMohammad Taheri
Jul 30, 2021·Experimental Cell Research·Ahmad BereimipourLeila Satarian

❮ Previous
Next ❯

Methods Mentioned

BETA
GTPase
biopsies
Assay
PCR
transfection
fluorescence microscopy

Software Mentioned

DIANA
PANTHER [UNK]
mirPath
microT
CXP
TargetScan
Floid
Statistica

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Related Papers

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Axel Hauschildweitere Mitglieder der Expertengruppe "melanozytäre Nävi"
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Axel Hauschildexpert group "Melanocytic nevi"
© 2022 Meta ULC. All rights reserved